Sepha launches small batch contract packaging service amid rising demand
The CPO's new division will offer a holistic blister packaging development service, complete with QA and non-destructive leak testing, encompassing material selection, tooling design, and 3D prototyping
Sepha has launched a contract packaging service to serve the pharmaceutical, nutraceutical, and medical device industries in response to what it described as a recent explosion in demand for small batch production.
A number of factors account for this surge in demand, including the rise of personalized medicines and orphan drugs, as well as the industry's need to produce small batches economically.
According to Paul Smith, Managing Director of Sepha, some customers were having to halt 24/7 high-speed blister lines to produce a few hundred sample packs. "This is not what these lines were designed for and cannot be justified in terms of line clearance and changeover times," he said.
This trend has led to larger pharmaceutical manufacturers and contract manufacturing organisations (CMOs) struggling to accommodate occasional low volumes on their high-speed production lines.
Sepha, therefore, has introduced the new service in response to this challenge amid increasing calls for support from its larger pharmaceutical customers.
"We see ourselves working in partnership rather than in competition with large CMOs," said Smith.
The company's new contract packaging offer focuses on providing cost-effective, low volume runs of blister and medical device packs within short turnarounds.
Operating from a new packaging facility in Belfast, the service produces packs for sampling, testing, and research, independent of the availability of larger blister pack lines.
Housing a range of blister packaging equipment, the facility accommodates the gamut of small-batch packaging projects, from cold-form and thermoform blisters to MAP packs, trays for medical devices, and temperature and humidity-controlled packaging.
The company's design experience enables them to offer a holistic blister packaging development service, complete with QA and non-destructive leak testing. Encompassing material selection, tooling design, and 3D prototyping, the full-service offering is geared to manufacturers looking to test or compare different materials and designs on a pilot scale.
The new contract packaging service targets companies looking to outsource anything from 100 up to 10,000 packs per week, either as one-off runs or longer-term contracts. These might be packs for use in stability studies, multiple formats for patient compliance testing, or marketing samples, for example.
Multinational pharmaceutical manufacturers wanting to focus on drug development and outsource the packaging of solid dose tablets, capsules, and medical devices will be the main beneficiaries.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance